Iverheal 12 Mg Tablet

Comprehensive Patient & Clinician Guide to Iverheal 12mg Tablet (Ivermectin)

Iverheal 12mg Tablet is a prescription anti-parasitic (anthelmintic) medication manufactured by Healing Pharma India Pvt. Ltd. Each tablet contains 12 mg of Ivermectin, an active chemical compound derived from macrocyclic lactones.

Iverheal 12mg is prescribed under specialist medical supervision to treat various parasitic infections affecting the intestinal tract, skin, eyes, and lymphatic system. By selectively targeting the nervous system of parasites, it causes paralysis and rapid clearance of the organism from the human host.

Mechanism of Action

Ivermectin works through selective, high-affinity binding to specific ion channels in invertebrate cells:

1. Glutamate-Gated Chloride Channel Binding: Ivermectin binds selectively to glutamate-gated chloride ion channels present in nerve and muscle cells of susceptible parasites.

2. Hyperpolarization: Binding increases the cell membrane’s permeability to chloride ions. The influx of chloride ions hyperpolarizes the cell membrane, blocking neuromuscular transmission.

3. Paralysis and Death: The resulting paralysis immobilizes the parasite, allowing the host’s immune system or digestive tract to naturally eliminate the organism.

Safety Nuance: Mammalian cells do not possess glutamate-gated chloride channels. Furthermore, ivermectin does not readily cross the blood-brain barrier in humans under normal physiological conditions, giving it a high margin of safety for vertebrate hosts when taken at recommended therapeutic doses.

Approved Therapeutic Indications

Iverheal 12mg Tablet is indicated for the treatment of various ectoparasitic and endoparasitic infections:

• Intestinal Strongyloidiasis: Infection of the gastrointestinal tract caused by the nematode Strongyloides stercoralis.

• Onchocerciasis (River Blindness): Parasitic disease affecting the skin and eyes caused by Onchocerca volvulus.

• Human Scabies: Infestation of the skin by the mite Sarcoptes scabiei (often used when topical treatments like permethrin cream fail or for crusted/severe scabies).

• Lymphatic Filariasis: Tissue and blood parasitic infection caused by Wuchereria bancrofti (typically administered as part of mass drug administration protocols).

Dosage and Administration Guidelines

Iverheal 12mg must be taken strictly according to the dosage and frequency prescribed by a physician, which is calculated based on the patient’s body weight and the specific underlying infection.

Administration Rules

• Empty Stomach Requirement: Take Iverheal 12mg on an empty stomach with a full glass of water. Food should not be consumed for at least 2 hours before and at least 1 hour after taking the dose. Food—especially high-fat meals—can significantly alter the absorption rate and bioavailability of ivermectin.

• Single-Dose Regimens: For many parasitic conditions (such as strongyloidiasis or scabies), Iverheal is prescribed as a single oral dose. In certain cases of scabies or onchocerciasis, a second dose may be scheduled 7 to 14 days later to kill newly hatched parasites.

• Swallow Whole: Swallow the tablet intact with water. Do not chew, crush, or split the tablet.

Potential Side Effects & Clinical Management

While Iverheal 12mg is generally well-tolerated, side effects can occur either as a direct response to the medication or as an immune reaction to dying parasites (Mazzotti reaction).

Common Side Effects

• Gastrointestinal: Mild nausea, diarrhea, vomiting, or abdominal discomfort.

• Neurological: Dizziness, mild headache, or drowsiness.

• Dermatological: Pruritus (itching), skin rash, or mild swelling.

Serious Adverse Reactions (Seek Immediate Medical Care)

• Mazzotti Reaction (Common in Onchocerciasis): Caused by the immune system reacting to dying microfilariae. Symptoms include severe fever, joint pain, tender/swollen lymph nodes, rapid heart rate, low blood pressure when standing (orthostatic hypotension), and eye inflammation.

• Central Nervous System Toxicity: Extreme drowsiness, confusion, loss of coordination (ataxia), or disorientation.

• Severe Cutaneous Reactions: Stevens-Johnson syndrome or toxic epidermal necrolysis, marked by painful spreading skin blisters or peeling skin.

Crucial Precautions & Clinical Safety Monitoring

• Loa Loa Co-Infection Warning: In patients co-infected with Loa loa (African eye worm), treatment with ivermectin can cause severe or life-threatening neurological reactions, including encephalopathy. Patients living in or traveling from endemic regions should be screened prior to therapy.

• Pediatric Safety: Safety and efficacy have not been established in pediatric patients weighing less than 15 kg.

• Pregnancy & Lactation:

  • Pregnancy: Not recommended during pregnancy unless explicitly deemed necessary by a physician, as risk data in pregnant women is limited.

  • Breastfeeding: Passes into breast milk in low concentrations. Caution is advised, and alternative feeding or temporary discontinuation should be discussed with a doctor.

• Liver & Kidney Impairment: Metabolized primarily in the liver. Patients with pre-existing liver disease should exercise caution and undergo routine monitoring.

Drug Interactions

• Warfarin & Blood Thinners: Ivermectin may enhance the anticoagulant effect of warfarin, increasing the risk of bleeding or bruising. Frequent INR monitoring is required if co-administered.

• GABA-Modulating Drugs: Co-administration with drugs that enhance GABA activity (such as benzodiazepines, barbiturates, or valproic acid) should be monitored closely due to potential additive central nervous system effects.

• Alcohol: Avoid consuming alcohol while taking Iverheal 12mg, as alcohol can worsen dizziness, drowsiness, and stomach discomfort.

Storage and Regulatory Compliance

• Storage Conditions: Store Iverheal 12mg Tablets at room temperature below 30°C (86°F). Keep away from excessive heat, direct light, and moisture.

• Keep Out of Reach: Keep out of reach of children and pets.

• Manufacturing Standards: Manufactured by Healing Pharma India Pvt. Ltd., Iverheal is produced in facilities adhering to WHO-GMP (World Health Organization Good Manufacturing Practices) guidelines.

Frequently Asked Questions (FAQs)

Q1: Do I need to take Iverheal 12mg every day for a long period?

No. In most cases, Iverheal is taken as a single one-time dose or as a short two-dose regimen spaced 1 to 2 weeks apart. Always follow the exact dosing schedule provided by your physician.

Q2: What should I do if I feel dizzy after taking the tablet?

Dizziness and lightheadedness can occur, especially when standing up quickly. Sit or lie down until the feeling passes, avoid driving or operating machinery while feeling dizzy, and ensure you stay well-hydrated.

Q3: Will I need follow-up tests after taking Iverheal?

Yes. Your doctor may order follow-up stool tests or skin scraping exams a few weeks after treatment to confirm that the parasite has been completely eradicated.

Medical Disclaimer

This guide is strictly for educational and informational purposes and should not replace professional medical advice, diagnosis, or treatment. Always consult a qualified physician or healthcare provider before initiating, modifying, or halting any anti-parasitic treatment or prescription medication schedule.

References

1. National Center for Biotechnology Information (NCBI):

   • StatPearls Review: Ivermectin Pharmacology, Indications, and Adverse Effects. https://www.ncbi.nlm.nih.gov/books/NBK537142/

   • PMC Clinical Studies: Ivermectin Safety in Human Helminthic Infections. https://pmc.ncbi.nlm.nih.gov/articles/PMC3108786/

2. U.S. Food and Drug Administration (FDA):

   • STROMECTOL (ivermectin) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020526s015lbl.pdf

3. MedlinePlus Drug Information (US National Library of Medicine):

   • Ivermectin Oral Route Monograph. https://medlineplus.gov/druginfo/meds/a607069.html

4. Mayo Clinic:

   • Ivermectin (Oral Route) Description, Dosage & Side Effects. https://www.mayoclinic.org/drugs-supplements/ivermectin-oral-route/description/drg-20064397